Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13366174 | 0.86 | BRAF (0.37) | HSD11B1 | |
| SCHEMBL2365656 | 0.85 | P2RX7 (0.39) | HSD11B1 | |
| SCHEMBL2365627 | 0.82 | IDH1 (0.57) | HSD11B1TYRO3 | |
| SCHEMBL2365608 | 0.81 | HSD11B1 (0.48) | HSD11B1TYRO3 | |
| SCHEMBL1168572 | 0.80 | HSD11B1 (0.48) | HSD11B1TYRO3MAPK8 | |
| SCHEMBL2369168 | 0.80 | HSD11B1 (0.47) | HSD11B1TYRO3MAPK8 | |
| SCHEMBL2365612 | 0.76 | HSD11B1 (0.47) | HSD11B1TYRO3 | |
| SCHEMBL1168285 | 0.74 | FAAH (0.48) | HSD11B1TYRO3 | |
| SCHEMBL3328670 | 0.74 | HSD11B1 (0.51) | HSD11B1MAPK8 | |
| SCHEMBL13366022 | 0.73 | BRAF (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | claimed |
| CN-102223797-A | Adamantyl benzamide compounds | HIGH POINT PHARMACEUTICALS LLC | 2011-10-19 | — | — | CN | claimed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | claimed |
| EP-2362730-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2011-09-07 | — | — | EP | claimed |
| WO-2010059618-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-27 | — | — | WO | claimed |
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| CN-102223797-A | Adamantyl benzamide compounds | HIGH POINT PHARMACEUTICALS LLC | 2011-10-19 | — | — | CN | disclosed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2362730-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010059618-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HSD11B1, HSD17B11, HSD3B1 | HSD11B1 1/4885TYRO3 4858/4885MAPK8 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.